Eric Lefkofsky Takes On Cancer With Tempus

Internet entrepreneur Eric Lefkofsky has an estimated net worth of nearly three billion dollars. In his career, he has been the driving force behind a number of companies that have the similarity of using big data to make big money. He is best known for leading the highly successful venture Groupon.

Tempus

Where Eric Lefkofsky is directing his passion these days is his new medical startup company Tempus, which is using artificial intelligence in no less of a pursuit than fighting cancer. As with his other companies, Tempus uses enormous amounts of data, in this case all related to cancer. Doctors send in information on specific tumors, and the team at Tempus then crunches the database searching for commonalities and patterns.

The emerging field is known as precision medicine, and while Tempus is currently focusing on cancer, the techniques the startup is pioneering may one day be used to fight other diseases such as diabetes and depression as well. Currently, it costs Tempus between $1,000 and $5,000 to do a single analysis, but this cost is dropping. There is intense interest in what Tempus is doing from many places, including the pharmaceutical industry.

A born entrepreneur

Eric Lefkofsky has been doing business his own way for a long time. As far back as his college days at the University of Michigan, he was selling carpets to make money. He founded his first company, InnerWorkings, a marketing venture, in 2001 and went on to run startups involved in logistics and advertising until finally hit the mother lode with Groupon.

A legacy project

Eric Lefkofsky hopes that Tempus will be his legacy project. When his wife was diagnosed with breast cancer in 2014, Lefkosky began researching the disease and was surprised to discover that there was not the massive amounts of data he anticipated and that what data did exist wasn’t being analyzed with the best tools. Motivated, he founded Tempus to fill the gap. The company is attracting more and more researchers who want to share their data, and a big breakthrough is expected soon.

Dr. Ira Kirschenbaum

Dr. Ira Kirschenbaum, recently underscored some of the most intriguing current developments in the sphere of orthopedics. His detailing of new and exciting orthopedic procedures is based on a report created by professionals in the field. the report was slated to be released in July of 2018.

 Dr. Ira Kirschenbaum is one of the foremost experts in the field of orthopedic technology and has accumulated advanced knowledge of surgery and other orthopedic procedures which has allowed him to share information that is relevant to those considering joint replacement. In-depth experience and knowledge of joint surgery is also valuable to investors in businesses that produce prosthetics and joint replacement implants. Dr. Ira Kirschenbaum has made a reputation for his novel approaches to Common surgical replacement procedures like those of the knee, hip, and shoulders.

Dr. Ira Kirschenbaum is perhaps most well known for creating a knee replacement procedure in which he utilizes a much smaller surgical cut than what would typically be needed in knee replacement surgery. Dr. Kirschenbaum only uses some of the joint, rather than the whole of the knee. This ensures that there is considerably less damage to nearby tissues. Less invasive procedures have allowing patients to enjoy major advantages, including an expedited recovery time and a higher efficient post surgery use of the joints.

Dr. Kirschenbaum has been an advocate for many procedures that are the result of rapidly changing technology. He believes that accessing the most advanced technological discoveries gives the surgeon advantages in precision, control, and efficiency in surgery.

 

Read more here

Interview with Dr. Ira Kirschenbaum, Joint Replacement Surgeon and Bronx Native

Entrepreneur Eric Lefkofsky Explains Why He Put His Latest Company Together

Eric Lefkofsky is a Chicago, Illinois, businessman who has co-founded multiple technology firms. Among these are InnerWorkings, Echo Global Logistics, MediaBank, and most famously Groupon. He has been a leader at these companies, including being the chief executive officer and chairman of the board. His latest company, Tempus, Inc. is bringing cutting-edge technology to the field of healthcare.

Tempus is a company that helps physicians deliver personalized care to cancer patients. His company built a library filled with data such as molecular data, clinical data, doctor’s notes, and genomic sequencing data. Machine learning and analytics sort this data and come up with relevant insights. Eric Lefkofsky says the goal is to help physicians develop individualized treatment plans that lead to better patient outcomes when diagnosed with this deadly disease.

He has partnered with many hospitals and universities around the nation. One of these is LSU Health Shreveport’s Feist-Weiller Cancer Center. This center is led by Maria-Magdalena Georgescu, M.D., Ph.D. She partnered with Tempus so that she could better research glioblastoma, a common and very deadly form of brain cancer. To date, people with this type of cancer face grim prospects because it grows too fast to be effectively targeted and treated.

Eric Lefkofsky says that the digital tools and analytics that his company provides to Feist-Weiller Cancer Center will help them better understand how their patient’s profiles, using their genetic information, will respond to various treatment options. They will be able to see what treatments can shrink or eliminate these types of tumors and lead to better patient outcomes.

Along with his long-time business partner, Eric Lefkofsky established Tempus in 2015. He says that he saw a need for much better technology when it comes to cancer care and decided he had the skills to fill it. He had gone along with a family member to their appointments to treat their cancer. He saw that physicians didn’t have access to the data that would help them better help their patients beat cancer. He put together a team of experts who built a platform that is now used for 25% of cancer patients in America.